M·CAM, Inc. releases Patently Obvious® on Celgard, LLC v. Sumitomo Chemical Co., Ltd.

Date:  Thu, 2013-02-28

CHARLOTTESVILLE, VA – February 28, 2013 – M·CAM, Inc. released its Patently Obvious® report today on Celgard, LLC v. Sumitomo Chemical Co., Ltd.

On February 22, 2013, Celgard, LLC filed a patent infringement claim against Sumitomo Chemical Co., Ltd. The complaint accuses Sumitomo of infringing Celgard’s U.S. Pat. No. 6,432,586 (hereafter ”˜586), which covers a separator technology for use in lithium ion batteries. Sumitimo is accused of willful infringement of the ”˜586 patent particularly through its sale of separators to Panasonic for use in the Toughbook line mobile computers.

Using the M·CAM DOORS™ analytic platform, an intellectual property analysis of Celgard’s ”˜586 patent was conducted in order to understand its strength and defensibility in the face of prior and concurrent art innovation. The innovation space surrounding the ”˜586 patent and its patent family members was examined to determine which patent or patents may provide alternatives to or alter the value of Celgard’s holdings.

M·CAM’s Patently Obvious® is a report providing visibility into potentially unconsidered alternatives, including art in the public domain, to patent holdings across a variety of technology areas.

M·CAM, Inc. is a global, full-service intellectual property and rights (IP&R) and intangible asset financial services firm. We provide the technical and financial systems that allow public and private markets to use IP&R and IA for regulated transactions in banking, securities, insurance, and public innovation investment and technology procurement. From our pioneering work in creating the world’s first standards-based innovation collateralization financial products for banking and securities to our work in grassroots innovator enablement and patent quality assurance programs, M·CAM provides the mechanism to balance the interests of public and commercial sectors to support and build thriving economies.

The M·CAM Patently Obvious® report on Celgard’s patent can be found HERE.